Average target for Moderna stock rises to USD 118.42

Published on 10/13/2026 at 17:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue was USD 145.00 million, up 2.00 percent. Moderna stock costs EUR 188.49 on October 13, 2026, with a bid of EUR 188.20.

Analyst target and valuation

Moderna's average analyst target rose from USD 116.84 to USD 118.42 on October 9, 2026.
Second-quarter 2026 revenue reached USD 145.00 million, up 2.00 percent year over year.
Moderna stock costs EUR 188.49 at Lang & Schwarz on October 13, 2026 at 5:09 p.m. CEST.
Moderna had a USD 84.1 billion market capitalization and a minus 26.42 P/E ratio on October 13, 2026.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

On October 9, 2026, estimates from 19 analysts lifted Moderna's average 12-month target from USD 116.84 to USD 118.42, as TradingView reported. Moderna's Nasdaq price was USD 211.84 at 11:17 a.m. ET on October 13, putting the target USD 118.42 44.10 percent below the US market price. At Lang & Schwarz, Moderna stock was trading at EUR 188.49 on October 13, 2026 at 5:09 p.m. CEST.

Revenue reached USD 145.00 million

Moderna's second-quarter 2026 revenue reached USD 145.00 million, up 2.00 percent from USD 142.00 million a year earlier. The figure came with a GAAP net loss of USD 782.00 million, while the loss per share was USD 1.97 versus USD 2.13 in the second quarter of 2025.

Yahoo Finance reported that management reiterated its expectation for revenue growth of up to 10.00 percent in 2026. The same earnings call put cash and investments at USD 6.90 billion at the end of the second quarter, giving investors a measurable balance-sheet reference as the company funds its pipeline.

Stock stays below its yearly high

The US price of USD 211.84 stood 6.87 percent below Moderna's 52-week high of USD 227.46 on October 13, 2026. The same quote showed a 52-week low of USD 22.28, leaving a wide price span between the low and the latest Nasdaq value.

The euro quotation gives German investors a separate trading perspective. Its bid was EUR 188.20 and its ask was EUR 188.78 at the Lang & Schwarz timestamp, a spread of EUR 0.58. The Nasdaq quote was still in its regular session at 11:17 a.m. ET, while the Lang & Schwarz quotation was in trading after 5:00 p.m. CEST.

Valuation and analyst expectations

Moderna's market capitalization was USD 84.1 billion on October 13, 2026, and its trailing P/E ratio was minus 26.42. The negative ratio reflects the company's reported loss rather than a positive earnings multiple. The USD 118.42 analyst target therefore sits materially below the latest USD 211.84 Nasdaq price, even after the target moved up from USD 116.84.

The valuation picture combines a large market value with continuing investment in vaccines and oncology programs. Revenue growth of up to 10.00 percent in 2026 is a management expectation, while the second-quarter revenue comparison shows only 2.00 percent year-over-year growth. That contrast makes the future pipeline contribution central to how the market assesses the shares.

Moderna stock stays below its high

At Lang & Schwarz, Moderna stock was trading at EUR 188.49 on October 13, 2026 at 5:09 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.